TREATMENT AND FEATURES OF HEREDITARY OVARIAN CANCER

The recurrence rate of ovarian cancer is up to 90%, which is associated with the asymptomatic course of the disease and the advanced stage of the tumor process at the time of diagnosis and the start of special treatment. Ovarian cancer (OC) in its course is recurrent. Hereditary ovarian cancer (HOC) is characterized by a more favorable course, which is mainly associated with a high response rate to platinum-containing drugs used to treat ovarian cancer (OC). It is with HOC that platinum-sensitive relapse is more common. For HOC, recurrence of the tumor process is characteristic in terms of 6 months or more after adjuvant treatment.Material and methods. For 5 years (from 2016 to 2021), a study of 123 patients with a clinical picture of HOC was carried out. The features of the clinical picture of HOC, indicators of overall and relapsefree survival were studied. The patients were divided into two groups according to the identified germline abnormalities in DNA (deoxyribonucleic acid) nucleotide sequences. To identify germline disorders, a standard diagnostic panel of DNA diagnostics of oncological diseases and new generation sequencing (NGS) were used.Results. The number of patients who did not undergo cytoreductive surgery in the group without germinal disorders was higher than in the main group (p = 0.044). In the comparison group, resistance to platinum drugs developed significantly more often (p = 0.007).When comparing the overall survival rate of women in the main group and the comparison group, no statistically significant dif-ferences were found (p = 0.69). Disease-free survival in patients with germline disorders was significantly higher than in patients without germline disorders (p = 0.004).. The highest rates of relapse-free survival were in patients with germline disorders in the BRCA1 gene. Disease-free survival rates were lower in patients with germline disorders in the BRCA2 gene and in the ATM and RAD50 genes.Conclusion. The absence of germline DNA abnormalities correlates with a more unfavorable prognosis of the course of the disease.

hereditary ovarian cancer, BRCA 1 and 2, platinum-sensitive relapse, survival

1. Ovarian cancer: Current status and strategies for improving therapeutic outcomes / A. Chandra, C. Pius, M. Nabeel [et al.] // Cancer Med. - 2019. - Vol. 8, № 16. - P. 7018-7031

2. Clinical Utility of Preoperative Assessment in Ovarian Cancer Cytoreduction / P. Koirala, A.S. Moon, L. Chuang/Р. Koirala // Diagnostics. - 2020. - Vol. 10, № 8. - P. 568

3. The impact of second-sixth line therapy on the survival of recurrent ovarian cancer after primary taxane / platinum therapy / L.C. Hanker, S. Loibl, N. Burchardi [et al.] // Ann. Oncol. - 2012. - Vol. 23. - P. 2605-2612

4. Most Commonly Mutated Genes in High-Grade Serous Ovarian Carcinoma Are Nonessential for Ovarian Surface Epithelial Stem Cell Transformation / R.J. Yamulla, S. Nalubola, A. Flesken-Nikitinet [et al.] // Cell Rep. - 2020. - Vol. 32, № 9. - P. 108086

5. Germ line mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer / F.J. Candido-dos- Reis, H. Song, E.L. Goode [et al.] // Clin. Cancer Res. - 2015. - Vol. 21, № 3. - P. 652-6576

6. Distinct molecular profiles in Lynch syndrome-associated and sporadic ovarian carcinomas / A. Niskakoski, S. Kaur, L. RenkonenSinisalo [et al.] // Int. J. Cancer. - 2013. - Vol. 133, № 11. - P. 2596-2608

7. Cytoreductive surgery for ovarian cancer: quality assessment / A.H. Brand // Ann. Oncol. - 2017. - Vol. 28, № 8. - P. 825-829